Elevated levels of Ajuba not only stimulate breast cancer cell growth but also contribute to tamoxifen resistance, making the Ajuba/DBC1/CBP/EP300 ternary complex a new promising target for breast cancer therapy. This evidence concerns the gene CCAR2 and breast carcinoma.